Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel Hormone Therapy Combined With Local Treatment in mHSCP Patients
NCT06832774Phase 2Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, randomised trial in prostate cancer (PCa) (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Progression free survival at 12 weeks. Started Aug 2025; status: recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06832774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06832774.